Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00199342 · ClinicalTrials.gov registry record · Phase 1
A Study of a Monoclonal Antibody, KW-2871, in Patients With Advanced Melanoma
A Phase 1 study, sponsored by Kyowa Kirin.
- Terminated
- Registry status
- Phase 1
- Development phase
- 5
- Enrollment target
NCT00199342 is a Phase 1 study that was terminated before completion, run by Kyowa Kirin. The registered enrollment target is 5 participants.
The verdict
NCT00199342, a Phase 1 study, was terminated before completion, sponsored by Kyowa Kirin.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 5 participants
- Enrollment target
Study Summary
This is a dose escalating cohort study to determine the maximum tolerated dose (MTD) of KW-2871 (in dose cohorts of 60, 80, and 100 mg/m2) when administered with a specified premedication regimen (ranitidine, diphenhydramine, and dexamethasone). KW-2871 will be administered at 14-day intervals.
Interventions
- DRUG KW-2871
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2004-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00199342
The ClinicalTrials.gov registry entry for NCT00199342 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Kyowa Kirin, which has 34 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which KW-2871 is the first listed.
NCT00199342 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00199342 about?
NCT00199342 is a clinical study titled "A Study of a Monoclonal Antibody, KW-2871, in Patients With Advanced Melanoma". This is a dose escalating cohort study to determine the maximum tolerated dose (MTD) of KW-2871 (in dose cohorts of 60, 80, and 100 mg/m2) when administered with a specified premedication regimen (ranitidine, diphenhydramine, and dexamethasone). KW-2871 will be administered at 14-day intervals.
What is the current status of trial NCT00199342?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 5 participants. The study started on 2004-11.
What interventions are being tested in trial NCT00199342?
The interventions under investigation include: KW-2871 (DRUG).
Who is sponsoring clinical trial NCT00199342?
This trial is sponsored by Kyowa Kirin, which has 34 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.